Comparative Pharmacology
Head-to-head clinical analysis: AZELEX versus DUAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZELEX versus DUAC.
AZELEX vs DUAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azelaic acid inhibits microbial protein synthesis and reduces the proliferation of Propionibacterium acnes. It also normalizes keratinization and has anti-inflammatory effects by scavenging free radicals.
DUAC (clindamycin 1% / benzoyl peroxide 5%) combines clindamycin, a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, and benzoyl peroxide, a keratolytic and antimicrobial agent that releases free radical oxygen, reducing Propionibacterium acnes and comedones.
Apply a thin layer to affected areas twice daily (morning and evening) or as directed by a physician. Topical use only.
Clindamycin 1% / benzoyl peroxide 5% gel: apply a thin film to affected areas twice daily (morning and evening).
None Documented
None Documented
Terminal elimination half-life is approximately 1-2 hours in patients with normal renal function; prolonged to 3-4 hours in renal impairment.
Terminal elimination half-life of clindamycin is 2.4 hours in adults with normal renal function; prolonged to 3.7-5.1 hours in hepatic impairment; clinical context: dosing interval may need adjustment in severe hepatic disease.
Primarily renal (~60% as unchanged drug and metabolites) and biliary/fecal (~40%).
Renal excretion of unchanged clindamycin (10%) and metabolites; biliary/fecal excretion of inactive metabolites; approximately 90% of dose recovered in urine and feces over 6 days.
Category C
Category C
Topical Acne Agent
Topical Acne Agent